Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Virginia (PRWEB) October 20, 2014 ... NDA Partners LLC, announced today that Ellen Teplitzky, ... legal support for the pharmaceutical industry, has joined ... manager of its legal services practice. NDA ... and expert witness and testimony, to top law ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
(Date:10/19/2014)... 2014 The Asian Automatic patient billing ... analysis and forecast of revenue. The Automatic patient billing ... $463.9 million by 2018, at a developing CAGR of ... TOC of the Asian Automatic patient billing market, to ... also provides a glimpse of the segmentation of this ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems report defines and ... of revenue. The Orthopedic braces and support systems market in ... 2018, at a developing CAGR of 4.4% from 2013 to ... braces and support systems market, to get an idea of ... the segmentation of orthopedic braces and support systems market in ...
Breaking Biology Technology:NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... 14 /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), a ... today announced that it will conclude enrolment next ... cartilage repair device, BST-CarGel(R). To date, the Company ... clinical sites will be permitted to enrol additional ...
... Va., Jan. 14 CEL-SCI CORPORATION , ... reports financial results for the fiscal year ended September 30, 2008.CEL-SCI ... a net loss of $(9,629,657) in fiscal year 2007. The ... $(0.07) compared to a net loss per common share in fiscal ...
... Comprehensive tutorials on the publicly available PROSITE, InterPro, IntAct and UniProt ... , ... Seattle (PRWEB) January 15, 2009 -- ... PROSITE, InterPro and IntAct, in addition to a newly updated tutorial ...
Cached Biology Technology:BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 2BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 3BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 4CEL-SCI Corporation Announces 2008 Financial Results 2CEL-SCI Corporation Announces 2008 Financial Results 3New and Updated Online Tutorials for PROSITE, InterPro, IntAct and UniProt 2New and Updated Online Tutorials for PROSITE, InterPro, IntAct and UniProt 3
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
(Date:10/14/2014)... fish oil supplements, rich in omega-3 fatty acids, do not ... which the heart can beat as fast as 150 beats ... the Montreal Heart Institute were published in the Journal ... , For the trial, 337 patients with atrial fibrillation not ... of fish oil a day or to placebo for up ...
(Date:10/14/2014)... by the Chinese Academy of Agricultural Sciences in Beijing, ... brief genomic history of tomato breeding, based on sequencing ... C.M. Rick Tomato Genetics Resource Center at UC Davis ... seed of both cultivated tomato varieties and related wild ... tomato genome sequence completed just two years ago, shows ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2
... MA (July 27, 2011) SomaLogic, Inc. and New ... entered into an exclusive licensing agreement whereby SomaLogic will ... several current and future NEB nucleic acid amplification and ... specific protein binding reagents based on chemically modified "aptamers," ...
... each other plant and harvest, rural Chinese neighbors also ... likely to reenroll their land in a conservation program ... Scientists from the Center for Systems Integration and Sustainability ... study the amount of land farmers in the Wolong ...
... NEW YORK (July 27, 2011) ... increasingly sophisticated illegal trade in wildlife parts conducted by organized crime, coupled ... rhinos, tigers, and elephants on a scale never before seen. , ... paper, published June 7 on the online issue of the journal ...
Cached Biology News:Farmers more likely to be green if they talk to their neighbors, according to MSU research 2Organized crime is wiping out wildlife 2
Whole rabbit blood (any breed, either sex) is collected at the time of slaughter and processed immediately at 4C, bottled, frozen and stored at -70C....
GlutaMAX-I Supplement...
Chemically Defined Lipid Concentrate...
... are membrane-filtered isotonic and enzyme-free aqueous ... cell-conditioning agents in either Ca2+- and ... Ca2+- and Mg2+-free phosphate-buffered saline ... from support substrates and each other ...
Biology Products: